Loading
NASDAQHealthcareBiotechnology
Latest quote
$4.90
$0.00 · 0.00%
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Previous close
$4.90
$0.00 · 0.00%
After-hours
$4.99
+$0.09 · +1.84%
Oct 9, 7:54 PM ET
Regular session · ET · Market data may be delayed.
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Day range
Current $4.90
52-week range
Current $4.90
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
37
Expensive
Sentiment
51
Mixed
Risk
47
Elevated Risk
Momentum
61
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Day range
Current $4.90
52-week range
Current $4.90
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cost of goods sold | 647K USD | 668K USD | — | — |
| Gross profit | −647K USD | −668K USD | — | — |
| Research and development | 60.26M USD | 57.29M USD | 40.63M USD | 34.61M USD |
| Selling, general, and administrative | 28.72M USD | 13.27M USD | 9.71M USD | 6.77M USD |
| Operating expenses | 88.34M USD | 69.89M USD | 50.33M USD | 41.37M USD |
| Interest income | 13.3M USD | 8.17M USD | 2.77M USD | 1.13M USD |
| Depreciation and amortization | 647K USD | 668K USD | 583K USD | 122K USD |
| Operating income | −88.98M USD | −70.56M USD | −50.33M USD | −41.37M USD |
| Net income | −75.27M USD | −61.69M USD | −47.26M USD | −40.24M USD |
Company facts updated Oct 10, 2026.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI5.64M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM2.42M0.00%78.27B USD0.19%$278.94+0.49%
Vanguard U.S. Momentum Factor ETFVFMO2.42M0.12%1.9B USD0.13%$230.11+1.02%
Vanguard Extended Market ETFVXF1.01M0.00%95.4B USD0.05%$235+0.80%
iShares Biotechnology ETFIBB1.01M0.01%10.28B USD0.44%$206.49+3.00%
iShares Russell 2000 Growth ETFIWO845.27K0.01%13.97B USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO637.97K0.00%18B USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA499.27K0.00%21.73B USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard U.S. Momentum Factor ETFVFMOVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
